The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1341
A Sumatriptan Needle-Free Injector for Migraine
The full article is available to subscribers Subscriber Login   
Revised 7/6/10: In Table 2, the injection volumes of Imitrex and Sumaval are listed as 5 mL. They should be 0.5 mL.

Sumatriptan was first marketed in the US in 1993 as Imitrex for subcutaneous injection, followed by tablets for oral administration and then by a nasal spray. It is one of seven serotonin receptor agonists (“triptans”) marketed in the US for treatment of migraine, but it is the only one available for subcutaneous injection.1 Now the FDA has approved Sumavel DosePro (Zogenix), a needle-free device for delivering sumatriptan succinate to subcutaneous tissue, for treatment of migraine and cluster headache in adults.

DELIVERY — A nitrogen gas-powered injection pushes the drug through the skin to subcutaneous tissue within one-tenth of a second; delivery of the drug with this device is bioequivalent to injection through a needle.2

EFFICACY — Subcutaneous injections of sumatriptan act more rapidly than oral or intranasal modes ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: A Sumatriptan Needle-Free Injector for Migraine
Article code: 1341c
 Electronic, downloadable article - $25